CTD2: Cancer Target Discovery and Development

The Cancer Target Discovery and Development (CTD2) Network, a functional genomics initiative, bridges the gap between cancer genomics and biology. The Network aims to understand how tumor heterogeneity leads to drug resistance in order to develop optimal combinations of chemotherapy or small molecules in combination with immunotherapy.?

Banner for CTD squared program. Links to CTD squared program page
Last updated: January 03, 2019

News & Publications

previousnext
Experimental settings and reagents used in the experimental pipelines underlying the two compared data sets.
CTD2
December 20, 2019

7x彩票网邀请码Genome-scale CRISPR-Cas9 viability screens performed in cancer cell lines provide a systematic approach to identify cancer dependencies and new therapeutic targets. As multiple large-scale screens become available, a formal assessment of the reproducibility of these experiments becomes necessary...

Antibody-dependent cell-mediated cytotoxicity
CTD2
December 19, 2019

Antibody-dependent cellular cytotoxicity (ADCC) is a key effector mechanism of natural killer (NK) cells mediated by therapeutic monoclonal antibodies (mAbs). This process is facilitated by the Fc receptor CD16a on human NK cells. CD16a appears to be the only activating receptor on NK cells...

Brain Cancer Regions
CTD2
December 05, 2019

The mechanistic target of rapamycin (mTOR) signaling is dysregulated prominently in human cancers including glioblastoma, suggesting mTOR as a robust target for therapy. Inhibitors of mTOR have had limited success clinically however, in part because their mechanism of action is cytostatic rather...

Chiu et al. (2018) Cell Reports. CC BY-NC-ND 4.0
CTD2
December 01, 2019

Background:?Long non-coding RNAs (lncRNAs) are emerging as important regulators of various biological processes. While many studies have exploited public resources such as RNA sequencing (RNA-Seq) data in The Cancer Genome Atlas to study lncRNAs in cancer, it is crucial to...

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer
CTD2
November 19, 2019

Androgen-receptor (AR) inhibitors, including enzalutamide, are used for treatment of all metastatic castration-resistant prostate cancers (mCRPCs). However, some patients develop resistance or never respond. We find that the transcription factor CREB5 confers enzalutamide resistance in an open...

O
O
O
O
O